BRAIN+ A/S - CVR: 36439440

2023, DKK

13.06.2024

Bruttoresultat

2.352'

Primær drift

-17.507'

Årets resultat

-19.125'

Aktiver

35.970'

Kortfristede aktiver

4.418'

Egenkapital

12.385'

Afkastningsgrad

-49 %

Soliditetsgrad

34 %

Likviditetsgrad

103 %

Resultat

13.06.2024

Årsrapport	2023 13.06.2024	2022 02.06.2023	2021 25.05.2022	2020 26.04.2021	2019 17.09.2020	2018 28.06.2019	2017 19.06.2018	2016 15.06.2017
Nettoomsætning
Bruttoresultat	2.352.491	3.232.617	3.992.214	6.394.383	5.736.776	6.084.454	4.342.938	1.973.596
Resultat af primær drift	-17.506.830	-11.084.452	-7.266.873	-1.024.432	-1.181.031	-500.725	-613.810	-499.140
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	20.236	17.221	103.877	0	31	97	89	166.667
Finansieringsomkostninger	-2.265.880	-47.021	-1.941.777	-227.902	-293.499	-103.112	-132.796	-167.042
Andre finansielle omkostninger	0	0	0	0	0	0	0	0
Resultat før skat	-19.752.474	-11.114.252	-9.104.773	-1.252.334	-1.474.499	-603.740	-746.517	-499.515
Resultat	-19.124.815	-9.679.595	-7.079.752	-978.100	-1.151.801	-462.187	-582.787	-389.776
Forslag til udbytte	0	0	0	0	0	0	0	0

Aktiver

13.06.2024

Årsrapport	2023 13.06.2024	2022 02.06.2023	2021 25.05.2022	2020 26.04.2021	2019 17.09.2020	2018 28.06.2019	2017 19.06.2018	2016 15.06.2017
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	1.326.916	2.013.956	3.330.145	718.120	766.484	195.911	638.787	645.309
Likvider	3.091.166	6.401.919	9.992.638	1.362.457	632.531	2.795.065	1.602.690	1.308.285
Kortfristede aktiver	4.418.083	8.415.875	13.322.783	2.080.577	1.399.015	2.990.976	2.241.477	1.953.594
Immaterielle aktiver og goodwill	31.551.697	36.844.737	33.415.724	23.804.946	17.266.180	19.766.267	13.994.106	9.171.434
Finansielle anlægsaktiver	0	0	0	0	0	0	0	18.000
Materielle aktiver	0	111.547	144.610	30.516	22.473	6.218	11.526	3.235
Langfristede aktiver	31.551.697	36.956.284	33.560.334	23.835.462	17.288.653	19.772.485	14.005.632	9.192.669
Aktiver	35.969.780	45.372.160	46.883.117	25.916.039	18.687.668	22.763.461	16.247.109	11.146.263

Aktiver

13.06.2024

Passiver

13.06.2024

Årsrapport	2023 13.06.2024	2022 02.06.2023	2021 25.05.2022	2020 26.04.2021	2019 17.09.2020	2018 28.06.2019	2017 19.06.2018	2016 15.06.2017
Forslag til udbytte	0	0	0	0	0	0	0	0
Egenkapital	12.384.756	16.382.902	20.604.018	4.105.265	5.083.365	6.235.166	6.697.353	6.080.302
Hensatte forpligtelser	0	0	457.299	1.507.978	1.782.212	1.672.098	1.813.651	1.967.274
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld			733.854	1.742.295	1.359.969	1.291.982	1.235.671	1.149.879
Leverandører af varer og tjenesteydelser	1.086.254	870.751	1.531.275	196.810	390.400	99.439	33.657	354.601
Kortfristede forpligtelser	4.300.129	7.090.533	25.087.946	18.173.876	10.132.372	13.564.215	6.500.434	1.948.808
Gældsforpligtelser	23.585.024	28.989.258	25.821.800	20.302.796	11.822.091	14.856.197	7.736.105	3.098.687
Forpligtelser	23.585.024	28.989.258	25.821.800	20.302.796	11.822.091	14.856.197	7.736.105	3.098.687
Passiver	35.969.780	45.372.160	46.883.117	25.916.039	18.687.668	22.763.461	16.247.109	11.146.263

Passiver

13.06.2024

Nøgletal

13.06.2024

Årsrapport	2023 13.06.2024	2022 02.06.2023	2021 25.05.2022	2020 26.04.2021	2019 17.09.2020	2018 28.06.2019	2017 19.06.2018	2016 15.06.2017
Afkastningsgrad	-48,7 %	-24,4 %	-15,5 %	-4,0 %	-6,3 %	-2,2 %	-3,8 %	-4,5 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-154,4 %	-59,1 %	-34,4 %	-23,8 %	-22,7 %	-7,4 %	-8,7 %	-6,4 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-772,6 %	-23.573,4 %	-374,2 %	-449,5 %	-402,4 %	-485,6 %	-462,2 %	-298,8 %
Soliditestgrad	34,4 %	36,1 %	43,9 %	15,8 %	27,2 %	27,4 %	41,2 %	54,6 %
Likviditetsgrad	102,7 %	118,7 %	53,1 %	11,4 %	13,8 %	22,1 %	34,5 %	100,2 %

Resultat

13.06.2024

Gæld

13.06.2024

Årsrapport

13.06.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 13.06.2024)

Beretning

13.06.2024

Dato for ledelsens godkendelse af årsrapporten:2024-05-07

Ledelsespåtegning:MANAGEMENT’S STATEMENTToday, the Executive Board and Board of Directors have considered and adopted the Annual Report of BRAIN+ A/S forthe financial year January 1st 2023 - December 31st 2023. The Annual Report is presented in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the assets, liabilities and financial position of theCompany at December 31st 2023 and of the results of the Company’s operations and cash ﬂow for the financial yearJanuary 1st 2023 - December 31st 2023. In our opinion, the Management Commentary includes a true and fair account of the matters addressed therein. We recommend that the Annual Report be adopted at the Annual General Meeting.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activitiesBrain+ is at the forefront of developing health tech solutions which can be certified as medical software for betterdementia management. The company aims to become the leading global dementia health tech provider with a vision toservice several million people aﬀected by dementia by 2030. The company’s dementia activities build on its legacy of developing gamified brain training software, its in-houseexpertise in medical device development and neuroscience combined with a broad international network ofcollaborations with leading experts in brain functioning and dementia.  With a focus on developing health tech solutionsfor people with dementia which have an outset in validated and recognized analogue methods for diagnosing andpreventing cognitive decline, Brain+ has developed three medical software platforms: Software-based CognitiveStimulation Therapy (CST), Computerized Cognitive Training (CCT) and Starry Night, a software tool for detection of earlyindications of dementia. From these health tech platforms, we are developing three specific products and one technology:CST-Assistant (v1. 0 commercially available, v2. 0 in regulatory phase with expected commercial release in2024): A health tech software product to support scalable and high-quality delivery of group CST via a readilyaccessible preparation system, content adaptability and a standardized delivery form, which lessens thedependence of CST performance on therapists. CST-Home Care (In late pilot phase development): Intended for use to extend and scale the delivery of CST to ahome setting, enabling broader access to the therapy for a larger dementia population at limited costs. CST/CCT Combination Product: Tailored for individuals with Mild Cognitive Impairment, combining CognitiveStimulation Therapy with Computerized Cognitive Training to improve cognitive function and potentially delay thetransition to dementia. Starry Night: A software based test designed to detect early signs of cognitive decline and enable early targetedintervention and treatment. In late 2022, Brain+ launched the initial commercial version 1. 0 of the CST-Assistant to gauge market reception andgather crucial feedback from early adopters. This marked the beginning of Brain+'s shift from solely a development-oriented entity to a comprehensive health tech company, culminating in the creation of an enhanced v2. 0 of theproduct. As Brain+ broadens its product range to introduce CST into patients' homes, the company remains committed toproviding innovative and convenient solutions that enhance patient well-being. 